Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Last Close
Jan 09  •  04:00PM ET
3.98
Dollar change
+0.15
Percentage change
3.92
%
Index- P/E- EPS (ttm)-0.28 Insider Own81.93% Shs Outstand78.29M Perf Week11.17%
Market Cap704.57M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float33.25M Perf Month-36.83%
Enterprise Value693.18M PEG- EPS next Q- Inst Own0.16% Short Float0.23% Perf Quarter-59.05%
Income-2.72M P/S26.24 EPS this Y- Inst Trans0.51% Short Ratio4.36 Perf Half Y-58.80%
Sales26.85M P/B2.15 EPS next Y- ROA-2.11% Short Interest0.08M Perf YTD7.86%
Book/sh1.85 P/C48.46 EPS next 5Y- ROE-2.41% 52W High17.17 -76.82% Perf Year-52.90%
Cash/sh0.08 P/FCF- EPS past 3/5Y- - ROIC-1.49% 52W Low3.25 22.46% Perf 3Y-28.05%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-23.97% -11.45% Gross Margin15.23% Volatility10.70% 9.32% Perf 5Y-
Dividend TTM- EV/Sales25.82 EPS Y/Y TTM74.15% Oper. Margin-7.91% ATR (14)0.42 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.33 Sales Y/Y TTM-10.12% Profit Margin-10.13% RSI (14)28.60 Recom-
Dividend Gr. 3/5Y- - Current Ratio1.82 EPS Q/Q-146.98% SMA20-9.21% Beta1.40 Target Price-
Payout- Debt/Eq0.01 Sales Q/Q13.92% SMA50-41.55% Rel Volume0.09 Prev Close3.83
Employees- LT Debt/Eq0.00 EarningsJul 24 BMO SMA200-57.90% Avg Volume17.41K Price3.98
IPOJan 12, 2021 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume1,588 Change3.92%
Oct-01-25 01:41PM
Jul-23-25 06:36AM
May-28-25 04:30PM
May-02-25 08:30AM
Apr-28-25 08:30AM
08:30AM Loading…
Apr-21-25 08:30AM
Mar-19-25 08:30AM
Feb-28-25 08:30AM
Feb-19-25 07:30AM
Dec-27-24 09:30AM
09:05AM
09:00AM
Dec-19-24 08:30AM
Nov-29-24 10:58AM
10:58AM
10:11AM Loading…
10:11AM
09:00AM
Nov-28-24 06:32AM
Nov-22-24 08:30AM
Oct-29-24 08:00AM
Aug-13-24 08:00AM
BGM Group Ltd. is a holding company, which engages in the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals. It operates through the following segments: Oxytetracycline and Licorice Products, and Traditional Chinese Medicine Derivatives (TCMD); Heparin Products and Sausage Casing; and Fertilizer. The Oxytetracycline and Licorice Products, and TCMD segment focuses on the development, manufacture, marketing, and sale of oxytetracycline products, licorice products, and TCMD. The Heparin Products and Sausage Casing segment treats cardiovascular diseases, cerebrovascular diseases, and hemodialysis. The Fertilizer segment includes Xiongguan, Organic Fertilizer and Xiongguan, and Organic-Inorganic Compound Fertilizer. The company was founded on February 7, 2019 and is headquartered in Chengdu, China.